Multiomic is a next-generation precision medicine business, applying computational systems biology to develop and commercialize data assets for metabolic syndrome — the world’s largest healthcare burden. With our unique combination of data science and biology expertise, we are enabling data-driven development of therapeutics and are bringing understanding into complex biological systems.
Metabolic syndrome, a cluster of closely-related diseases (atherosclerotic cardiovascular disease, type 2 diabetes, chronic kidney disease, non-alcoholic fatty liver) with many common risk factors, is costing the healthcare system $2 trillion (forecast >$5.5 trillion by 2040). It is a 1.6x larger market than oncology, yet attracts only 40% of the VC dollars.
CHRONIC KIDNEY DISEASE
NON-ALCOHOLIC FATTY LIVER
A major unmet need is the lack of high-fidelity tools to focus the right treatments on the right patients. In oncology, treatments are personalized based on genetic and protein biomarkers whereas metabolic syndrome patients are being prescribed drugs based on their blood pressure, fasting glucose and cholesterol levels. As metabolic syndrome is a complex multifactorial condition, it requires systems medicine models and composite biomarkers that were hitherto infeasible. ML-enabled data science and rapidly-falling omics costs have changed the game and we are aiming at becoming the leader in this space
METABOLIC SYNDROME PANDEMIC
please view sidebar for data sources.
WHAT WE DO
MULTI Omic ANalysis.
How someone's genes predispose disease and influence drug response
How ageing and external factors affect gene expression
Which genes are actually expressed i.e. instructions generated to make proteins
Which proteins are actually produced
Which byproducts of metabolism are generated
Which gut bacteria influence metabolism
UNDERSTANDING CHRONIC DISEASE BIOLOGY
EXPERTS IN THEIR FIELDS
Co-founder & CEO
30+ years in biopharma & healthcare, focusing on R&D management, B2B partnerships and value creation strategy. Has engaged with over 100 organizations in biopharma, medical technology and healthcare. Published authority on biopharma R&D partnerships and biotech business models
CHIEF TECHNOLOGY OFFICER
Deep technical capabilities, strong academic network and author of multiple scientific papers on system biology modeling of cardiometabolic diseases. Most recent prior role was leading a data science team at a Boston-based biotech that was acquired for >$2 billion
CHIEF SCIENCE OFFICER
Forbes 30 under 30. Founded The Longevity Labs, whose nutraceutical is now marketed in >14 countries including USA, exited after 3 years. Leadership experience with two other startups in cancer genomics and AI-enabled robotics.
Celia Antonio Schell
VP STUDY & PARTNERSHIP OPERATIONS
14 years experience in clinical research at Novartis and ICON. Recently managed a global Phase III clinical trial of >7,000 cardiovascular patients across 43 countries.
Lead DATA SCIENTIST
Accomplished systems biology modeler. Most recently at the European Bioinformatics Institute. Prior to this, conducted academic research including journal papers on systems biology modeling of atherosclerosis.
CHIEF OF STAFF & FINANCE MANAGER
Broad experience base of international collaborative activities. Product manager in a B2B financial data & solutions provider. Project manager in an energy & fintech business. Founded & exited own business.
Experienced at analyzing and interpreting multi-omic patient and in vitro/in vivo data. Previously in the translational medicine data science team at Benevolent AI.
BUSINESS DEVT. & ALLIANCE MGMT.
Analyst working across the bioscience and business interface with Master’s degree in Bioscience Entrepreneurship and Bachelor’s degree in biochemistry. Previous experience working in a range of healthcare-centred roles, spanning project support in primary care training to life sciences public relations
PARTNERSHIPS & CORPORATE DEVT.
Analyst working at the cross-section of business and bioscience, with an MSc in Bioscience Entrepreneurship and a BSc in Biomedical Sciences. Prior experience includes working in bioscience SMEs across marketing and business development functions, as well as pharmaceutical R&D
Experienced at analyzing high-dimensional omics datasets and building bioinformatics pipelines. Previously a postdoc at Imperial College London.
SCIENCE & BUSINESS ANALYST
Previously interned at Immunocore, AstraZeneca and the Wellcome Sanger Institute.
MULTIOMIC HEALTH IS A MEMBER OF
Want to be a part of our team?
Got a partnership in mind?
Get in touch with us and know more about how we are changing the face of healthcare.
Multiomic Health Limited is a registered UK company
25 City Road, Shoreditch, London, EC1Y 1AA